Efficacy and tolerability of capmatinib in a very elderly patient with metastatic NSCLC harboring a MET exon 14 mutation

References

• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Lamberti G, Andrini E, Sisi M, et al. Beyond EGFR, ALK and ROS1: current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma. Crit Rev Oncol Hematol. 2020;156:103119. doi:10.1016/j.critrevonc.2020.103119
   PubMed Web of Science ®Google Scholar
• De Maglio G, Pasello G, Dono M, et al. The storm of NGS in NSCLC diagnostic-therapeutic pathway: how to sun the real clinical practice. Crit Rev Oncol Hematol. 2022;169:103561. doi:10.1016/j.critrevonc.2021.103561
   PubMed Web of Science ®Google Scholar
• Dall'Olio FG, Conci N, Rossi G, et al. Comparison of sequential testing and next generation sequencing in advanced lung adenocarcinoma patients - a single centre experience. Lung Cancer. 2020;149:5–9. doi:10.1016/j.lungcan.2020.08.008
   PubMed Web of Science ®Google Scholar
• Mazieres J, Vioix H, Pfeiffer BM, et al. MET Exon 14 skipping in NSCLC: a systematic literature review of epidemiology, clinical characteristics, and outcomes. Clin Lung Cancer. 2023;24(6):483–497. doi:10.1016/j.cllc.2023.06.008
   PubMed Web of Science ®Google Scholar
• Sabari JK, Montecalvo J, Chen R, et al. PD-L1 expression and response to immunotherapy in patients with MET exon 14-altered non-small-cell lung cancers (NSCLC). J Clin Oncol. 2017; 35: 8512. doi:10.1200/JCO.2017.35.15_suppl.8512
   Google Scholar
• Wolf J, Seto T, Han JY, et al. GEOMETRY mono-1 investigators. Capmatinib in MET Exon 14-mutated or MET-amplified non-small-cell lung cancer. N Engl J Med. 2020;383(10):944–957. doi:10.1056/NEJMoa2002787
   PubMed Web of Science ®Google Scholar
• Paik PK, Felip E, Veillon R, et al. Tepotinib in non-small-cell lung cancer with MET Exon 14 skipping mutations. N Engl J Med. 2020;383(10):931–943. doi:10.1056/NEJMoa2004407
   PubMed Web of Science ®Google Scholar
• Fujino T, Suda K, Mitsudomi T. Lung cancer with METexon 14 skipping mutation: genetic feature, current treatments, and future challenges. Lung Cancer (Auckl). 2021;12:35–50. doi:10.2147/LCTT.S269307
   PubMed Web of Science ®Google Scholar
• Sabari JK, Leonardi GC, Shu CA, et al. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. Ann Oncol. 2018;29(10):2085–2091. doi:10.1093/annonc/mdy334
   PubMed Web of Science ®Google Scholar
• Schoenfeld AJ, Rizvi H, Bandlamudi C, et al. Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. Ann Oncol. 2020;31(5):599–608. doi:10.1016/j.annonc.2020.01.065
   PubMed Web of Science ®Google Scholar
• Dudnik E, Bshara E, Grubstein A, et al. Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): outcomes with immune check-point inhibitors (ICPi). Lung Cancer. 2018;124:117–124. doi:10.1016/j.lungcan.2018.07.044
   PubMed Web of Science ®Google Scholar
• Mazieres J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019;30(8):1321–1328. doi:10.1093/annonc/mdz167
   PubMed Web of Science ®Google Scholar
• Guisier F, Dubos-Arvis C, Viñas F, et al. Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced NSCLC with BRAF, HER2, or MET mutations or RET translocation: GFPC 01-2018. J Thorac Oncol. 2020;15(4):628–636. doi:10.1016/j.jtho.2019.12.129
   PubMed Web of Science ®Google Scholar
• Inno A, Bogina G, Settanni G, et al. First-line tepotinib for a very elderly patient with metastatic NSCLC harboring MET exon 14 skipping mutation and high PD-L1 expression. Drug Target Insights. 2023;17:110–113. doi:10.33393/dti.2023.2626
   PubMed Web of Science ®Google Scholar
• Lin JJ, Chin E, Yeap BY, et al. Increased hepatotoxicity associated with sequential immune checkpoint inhibitor and crizotinib therapy in patients with Non-small cell lung cancer. J Thorac Oncol. 2019;14(1):135–140. doi:10.1016/j.jtho.2018.09.001
   PubMed Web of Science ®Google Scholar
• Yamaguchi O, Kaira K, Kawasaki T, et al. Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non-small cell lung cancer harboring EGFR mutation. Thorac Cancer. 2020;11(4):1045–1051. doi:10.1111/1759-7714.13363
   PubMed Web of Science ®Google Scholar
• Chour A, Denis J, Mascaux C, et al. Brief report: severe sotorasib-related hepatotoxicity and non-liver adverse events associated with sequential anti-programmed cell death (ligand)1 and sotorasib therapy in KRASG12C-mutant lung cancer. J Thorac Oncol. 2023;18(10):1408–1415. doi:10.1016/j.jtho.2023.05.013
   PubMed Web of Science ®Google Scholar
• Gelsomino F, Vitale G, Raschi E, Ardizzoni A. Severe liver injury triggered by sequential use of immune checkpoint blockers and tyrosine kinase inhibitors: an emerging clinical issue. J Thorac Oncol. 2023;18(10):e112–e113. doi:10.1016/j.jtho.2023.07.002
   PubMed Web of Science ®Google Scholar
• Vansteenkiste JF, Smit EF, Groen HJM, et al. Capmatinib in patients with METex14-mutated advanced nonsmall cell lung cancer who received prior immunotherapy: the Phase II GEOMETRY mono-1 study. Ann Oncol. 2020;31(Suppl. 4):S830.
   PubMedGoogle Scholar
• Sisi M, Vitale G, Fusaroli M, et al. Capmatinib-induced liver injury as emerging toxicity of MET inhibitors in patients with NSCLC pretreated with immune checkpoint inhibitors. JTO Clin Res Rep. 2023;4(9):100563. doi:10.1016/j.jtocrr.2023.100563
   PubMedGoogle Scholar
• Lau SCM, Perdrizet K, Fung AS, et al. Programmed cell death protein 1 inhibitors and MET targeted therapies in NSCLC with MET Exon 14 skipping mutations: efficacy and toxicity as sequential therapies. JTO Clin Res Rep. 2023;4(10):100562. doi:10.1016/j.jtocrr.2023.100562
   PubMedGoogle Scholar